Sildenafil in the treatment of erectile dysfunction after radical prostatectomy

Zagaja, Gregory P.; Mhoon, Deborah A; Aikens, James E.; Brendler, Charles B.

doi:10.1016/s0090-4295(00)00659-2

Cited by 122 publications

(72 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that sildenafil as well as the other currently available phosphodiesterase type 5 inhibitors, such as vardenafil and tadalafil, may not be such effective in the early phase of nerve healing as documented by the clinical inefficacy of sildenafil in the first 9 months after the NSRP. 25 Notably, Schwarts et al 22 reported a 20% dropout rate due to pharmacological side effects in postradical prostatectomy patients enrolled in a trial on daily sildenafil 50 and 100 mg, respectively, for 6 months. This observation raises issues about patients' compliance with the required schedule of sildenafil prophylaxis.…”

Section: Patients Bother For Sexual Function After Nsrpmentioning

confidence: 99%

Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP)

Gontero

Kirby

2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Section: Patients Bother For Sexual Function After Nsrpmentioning

confidence: 99%

Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP)

Gontero

Kirby

2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…Response rates with sildenafil in this patient group depend on whether nerve-sparing techniques are used, with the highest response rate in bilateral nerve-sparing procedures (80%), followed by 50% in unilateral nerve-sparing surgery, and only 15% in the absence of nerve-sparing techniques. 30 -32 In a recent study, Zagaja et al 32 showed that younger patients and those treated with bilateral nervesparing technique are more likely to be potent postoperatively. On the other hand, early nonresponse to sildenafil in patients who have undergone radical prostatectomy should not be considered as a failure, since the likelihood of response increases over time.…”

Section: Patients Undergoing Radical Prostatectomymentioning

confidence: 99%

Sildenafil citrate: lessons learned from 3 years of clinical experience

Hatzichristou

2002

Int J Impot Res

View full text Add to dashboard Cite

“…After radical prostatectomy, 29 -53% of men report a positive response. [2][3][4][5][6] Men who are younger, who undergo bilateral nerve-sparing surgery, and ware are at least 1 year postsurgery are more likely to fall into this group. [3][4][5][6] The positive response rate to sildenafil after radiation therapy for localized prostate carcinoma varies from 50% to 91%, with higher success rates reported among men who received brachytherapy.…”

mentioning

confidence: 99%

The use of treatments for erectile dysfunction among survivors of prostate carcinoma

Schover

Fouladi

Warneke

et al. 2002

Cancer

116

View full text Add to dashboard Cite

BACKGROUNDThe objectives of this survey were to describe the prevalence of using a treatment for erectile dysfunction (ED) among men after therapy for localized prostate carcinoma and to construct models explaining the variance in trying a treatment, treatment success, and adherence to treatment.METHODSA postal survey was sent to 2636 men in The Cleveland Clinic Foundation's Prostate Cancer Registry who were treated initially with either definitive radiotherapy or prostatectomy for localized prostate carcinoma. The survey asked about demographic items, past and current sexual functioning, and the partner's sexual function. Men were asked about their current and intended use of medical treatments for ED. Standardized questionnaires included the Sexual Self‐Schema Scale‐Male Version, the International Index of Erectile Function, urinary and bowel symptom scales from the Los Angeles Prostate Cancer Index), and the Short‐Form Health Survey.RESULTSThe return rate was 49%. Differences between men who returned the questionnaire and men who did not respond suggest that the sample was weighted toward men who were more interested in staying active sexually. ED was a problem for 85% of men, and 59% of this group used at least 1 treatment for ED. Only 38% of men found that a medical treatment was at least somewhat helpful in improving their sex lives, however, and 30% of respondents still were using at least 1 treatment at the time of the survey. Factors that were associated with the efficacy of treatments for ED and with their continued use included having a sexual partner, younger age, choosing a treatment for prostate carcinoma that was more likely to spare some sexual function, and not having had neoadjuvant or current antiandrogen therapy. Men who tried a greater number of treatments for ED were more likely to find one that worked. Men were more likely to continue using treatments for ED that produced greater improvements in sexual function.CONCLUSIONSThe success of medical treatments for men with ED among long‐term survivors of prostate carcinoma is limited. Men prefer noninvasive treatments, although invasive treatments are more effective. Sexual counseling for men and their partners is recommended, because it may increase the use of medical therapies for ED. Creating more realistic expectations in both partners also may enhance treatment adherence. Cancer 2002;95:2397–407. © 2002 American Cancer Society.DOI 10.1002/cncr.10970

show abstract

Sildenafil in the treatment of erectile dysfunction after radical prostatectomy

Cited by 122 publications

References 12 publications

Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP)

Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP)

Sildenafil citrate: lessons learned from 3 years of clinical experience

The use of treatments for erectile dysfunction among survivors of prostate carcinoma

Contact Info

Product

Resources

About